N/A N=126 Efficacy and Safety of Nerivio Device for Acute Treatment of Migraine in People With Chronic Migraine
Chronic Migraine
Primary: Pain Relief at 2 Hours Post-treatment — 54 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=166 Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference — 66; 71; 6; 5 Participants
Phase 2 N=19 GTx-024 as a Treatment for Stress Urinary Incontinence in Women
Stress Urinary Incontinence
Primary: The Mean Percent Change in Number of Stress Incontinence Episodes/Day as Assessed by Patient Completion of the 3 Day Voiding Diary — 81 percent reduction
Phase 2 N=20 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency
Sphingomyelin Lipidosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 9; 7; 20 Participants
Phase 3 N=664 MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
NSCLC Stage IV
Primary: Primary Efficacy Analysis of Overall Response Rate ( ORR) of MYL-1402O as Compared to Avastin — 140; 144; 197; 190 Participants
N/A N=15 INDividualised EXercise for Kneecap Dislocations
Patella Dislocation · Patella Dislocation Recurrent
Primary: Eligibility Rate — 15 Participants
Phase 2 N=247 A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)] — -1.33; -1.15 Percentage point of HbA1c — p=0.0818
Phase 2 N=211 The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis
Primary: Clinical Remission — 5; 2; 9; 4 Participants — p=0.1806
N/A N=329 Trifecta™ Long Term Follow-Up (LTFU) Study
Aortic Valve Insufficiency · Aortic Valve Regurgitation · Aortic Valve Stenosis
Primary: Percentage of Participants With Freedom From Reoperation for Structural Valve Deterioration at 10 Years Post-Implant — 75.7 Percentage of Participants
Phase 1 N=49 A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers
Healthy Volunteers · Male · Japanese
Primary: Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)] — 30200000; 29000000 ng*h/mL
Phase 2 N=41 Dexamethasone Dyspnea Study
Advanced Cancers · Hematologic Disorder · Solid Tumors
Primary: Number of Participants Who Completed the Dyspnea Numeric Rating Scale — 18; 17 Participants
N/A N=14 Early Experience of a New Implant System for Bone Conduction Hearing in the Pediatric Population
Unilateral Mixed Conductive and Sensorineural Hearing Loss (Diagnosis) · Sensorineural Hearing Loss, Unilateral With Normal Hearing on the Contralateral Side
Primary: Number of Participants Reporting Type and Severity of Adverse Events in the Pediatric Population Implanted With the Osia System — 1; 1; 1; 1 Participants
Early Phase 1 N=10 Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women
Obesity
Primary: To Determine Whether Oral Administration of Celebrex to Obese Women Will Reduce the PGE-M in Urine
N/A N=14 RISA Extension Study - Long Term Safety
Asthma
Primary: Percentage of Subjects With Respiratory Adverse Events (AEs) in Annual Increments — 78.6; 85.7; 83.3; 100 percentage subjects with respiratory AEs
Phase 1 N=74 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD) — 0.0; 20.0; 20.0; 60.0 percentage of participants